Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 5th edition, 486 pages Free download

Malignant Melanoma

Free Subscription Articles published in Cancer Res Retrieve available abstracts of 113 articles: HTML format

Single Articles

October 2020
1. PAUDEL BB, Lewis JE, Hardeman KN, Hayford CE, et al
   An Integrative Gene Expression and Mathematical Flux Balance Analysis Identifies Targetable Redox Vulnerabilities in Melanoma Cells.
   Cancer Res. 2020;80:4565-4577.
   PubMed     Abstract available
   
   
   September 2020
2. BELLERI M, Paganini G, Coltrini D, Ronca R, et al
   BETA-GALACTOSYLCERAMIDASE PROMOTES MELANOMA GROWTH VIA MODULATION OF CERAMIDE METABOLISM.
   Cancer Res. 2020 Sep 30. pii: 0008-5472.CAN-19-3382.
   PubMed     Abstract available
   
   
   July 2020
3. PORTA C, Consonni FM, Morlacchi S, Sangaletti S, et al
   Tumor-Derived Prostaglandin E2 Promotes p50 NF-kappaB-Dependent Differentiation of Monocytic MDSCs.
   Cancer Res. 2020;80:2874-2888.
   PubMed     Abstract available
   
   
   June 2020
4. KALLIO P, Jokinen E, Hogstrom J, Das S, et al
   Blocking Angiopoietin-2 Promotes Vascular Damage and Growth Inhibition in Mouse Tumors Treated with Small Doses of Radiation.
   Cancer Res. 2020;80:2639-2650.
   PubMed     Abstract available
   
   
   
5. TAHTINEN S, Feola S, Capasso C, Laustio N, et al
   Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy.
   Cancer Res. 2020;80:2575-2585.
   PubMed     Abstract available
   
   
   
6. VANDAMME N, Denecker G, Bruneel K, Blancke G, et al
   The EMT transcription factor ZEB2 promotes proliferation of primary and metastatic melanoma while suppressing an invasive, mesenchymal-like phenotype.
   Cancer Res. 2020 Jun 5. pii: 0008-5472.CAN-19-2373.
   PubMed     Abstract available
   
   
   April 2020
7. ABDUL PARI AA, Singhal M, Hubers C, Mogler C, et al
   Tumor cell-derived Angiopoietin-2 promotes metastasis in melanoma.
   Cancer Res. 2020 Apr 17. pii: 0008-5472.CAN-19-2660.
   PubMed     Abstract available
   
   
   
8. PATEL A, Fraile Garcia L, Mannella V, Gammon L, et al
   Targeting p63 upregulation abrogates resistance to MAPK inhibitors in melanoma.
   Cancer Res. 2020 Apr 14. pii: 0008-5472.CAN-19-3230.
   PubMed     Abstract available
   
   
   March 2020
9. GIRARD CA, Lecacheur M, Ben Jouira R, Berestjuk I, et al
   A feed-forward mechanosignaling loop confers resistance to therapies targeting the MAPK pathway in BRAF-mutant melanoma.
   Cancer Res. 2020 Mar 16. pii: 0008-5472.CAN-19-2914.
   PubMed     Abstract available
   
   
   
10. SANTANA-MAGAL N, Farhat-Younis L, Gutwillig A, Gleiberman A, et al
    Melanoma-secreted lysosomes trigger monocyte-derived dendritic cell apoptosis and limit cancer immunotherapy.
    Cancer Res. 2020 Mar 3. pii: 0008-5472.CAN-19-2944.
    PubMed     Abstract available
    
    
    February 2020
11. THORKELSSON A, Merlino G, Michael H
    Build-a-Mouse: Melanoma Modeling Picks up Speed.
    Cancer Res. 2020;80:655-656.
    PubMed     Abstract available
    
    
    
12. MELMS JC, Vallabhaneni S, Mills CE, Yapp C, et al
    Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity.
    Cancer Res. 2020;80:798-810.
    PubMed     Abstract available
    
    
    January 2020
13. KIM YJ, Tsang T, Anderson GR, Posimo JM, et al
    Inhibition of BCL2 family members increases the efficacy of copper chelation in BRAFV600E-driven melanoma.
    Cancer Res. 2020 Jan 31. pii: 0008-5472.CAN-19-1784.
    PubMed     Abstract available
    
    
    
14. GARTRELL-CORRADO RD, Chen AX, Rizk EM, Marks DK, et al
    Linking transcriptomic and imaging data defines features of a favorable tumor immune microenvironment and identifies a combination biomarker for primary melanoma.
    Cancer Res. 2020 Jan 16. pii: 0008-5472.CAN-19-2039.
    PubMed     Abstract available
    
    
    December 2019
15. FAILMEZGER H, Muralidhar S, Rullan A, de Andrea CE, et al
    Topological Tumor Graphs: a graph-based spatial model to infer stromal recruitment for immunosuppression in melanoma histology.
    Cancer Res. 2019 Dec 24. pii: 0008-5472.CAN-19-2268.
    PubMed     Abstract available
    
    
    
16. BOUSSOUAR A, Tortereau A, Manceau A, Paradisi A, et al
    Netrin-1 and its receptor DCC are causally implicated in melanoma progression.
    Cancer Res. 2019 Dec 5. pii: 0008-5472.CAN-18-1590.
    PubMed     Abstract available
    
    
    November 2019
17. BOK I, Vera O, Xu X, Jasani N, et al
    A versatile ES cell-based melanoma mouse modeling platform.
    Cancer Res. 2019 Nov 19. pii: 0008-5472.CAN-19-2924.
    PubMed     Abstract available
    
    
    
18. MURALIDHAR S, Filia A, Nsengimana J, Pozniak J, et al
    Vitamin D-VDR signaling inhibits Wnt/beta-catenin-mediated melanoma progression and promotes anti-tumor immunity.
    Cancer Res. 2019 Nov 5. pii: 0008-5472.CAN-18-3927.
    PubMed     Abstract available
    
    
    October 2019
19. PANKA DJ, Wang W, Atkins MB, Mier JW, et al
    Retraction: The Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma Cells.
    Cancer Res. 2019;79:5459.
    PubMed    
    
    
    
20. TRAVNICKOVA J, Wojciechowska S, Khamseh A, Gautier P, et al
    Zebrafish MITF-low melanoma subtype models reveal transcriptional subclusters and MITF-independent residual disease.
    Cancer Res. 2019 Oct 3. pii: 0008-5472.CAN-19-0037.
    PubMed     Abstract available
    
    
    
21. BOUKERCHE H, Su ZZ, Emdad L, Baril P, et al
    Editor's Note: mda-9/Syntenin: A Positive Regulator of Melanoma Metastasis.
    Cancer Res. 2019;79:5127.
    PubMed    
    
    
    September 2019
22. NEVALA WK, Buhrow SA, Knauer DJ, Reid JM, et al
    Correction: Antibody-Targeted Chemotherapy for the Treatment of Melanoma.
    Cancer Res. 2019;79:4551.
    PubMed    
    
    
    August 2019
23. FEDDERSEN CR, Schillo JL, Varzavand A, Vaughn HR, et al
    Src-dependent DBL family members drive resistance to vemurafenib in human melanoma.
    Cancer Res. 2019 Aug 15. pii: 0008-5472.CAN-19-0244.
    PubMed     Abstract available
    
    
    
24. LISCHER C, Eberhardt M, Jaitly T, Schinzel C, et al
    Curatopes Melanoma: a database of predicted T cell epitopes from overly expressed proteins in metastatic cutaneous melanoma.
    Cancer Res. 2019 Aug 15. pii: 0008-5472.CAN-19-0296.
    PubMed     Abstract available
    
    
    July 2019
25. FLEMING V, Hu X, Weller C, Weber R, et al
    Melanoma extracellular vesicles generate immunosuppressive myeloid cells by PD-L1 upregulation via TLR4 signaling.
    Cancer Res. 2019 Jul 23. pii: 0008-5472.CAN-19-0053.
    PubMed     Abstract available
    
    
    
26. SACHDEVA R, Wu M, Smiljanic S, Kaskun O, et al
    ID1 Is Critical for Tumorigenesis and Regulates Chemoresistance in Glioblastoma.
    Cancer Res. 2019 Jul 10. pii: 0008-5472.CAN-18-1357.
    PubMed     Abstract available
    
    
    June 2019
27. SAHU RP
    Deciphering Mechanisms of UVR-Induced Tumoral Immune Checkpoint Regulation against Melanoma.
    Cancer Res. 2019;79:2805-2807.
    PubMed     Abstract available
    
    
    May 2019
28. ANICHINI A
    Progress in Understanding Complexity and Determinants of Immune-Related Prognostic Subsets in Primary Melanoma.
    Cancer Res. 2019;79:2457-2459.
    PubMed     Abstract available
    
    
    
29. YOO JH, Brady SW, Acosta-Alvarez L, Rogers A, et al
    The small GTPase ARF6 activates PI3K in melanoma to induce a pro-metastatic state.
    Cancer Res. 2019 May 2. pii: 0008-5472.CAN-18-3026.
    PubMed     Abstract available
    
    
    April 2019
30. SHIDAL C, Singh NP, Nagarkatti P, Nagarkatti M, et al
    MicroRNA-92 expression in CD133+ melanoma stem cells regulates immunosuppression in the tumor microenvironment via integrin-dependent activation of TGF-beta.
    Cancer Res. 2019 Apr 23. pii: 0008-5472.CAN-18-2659.
    PubMed     Abstract available
    
    
    
31. EMMONS MF, Faiao-Flores F, Sharma R, Thapa R, et al
    HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy.
    Cancer Res. 2019 Apr 15. pii: 0008-5472.CAN-19-0040.
    PubMed     Abstract available
    
    
    
32. SHAH R, Singh SJ, Eddy K, Filipp FV, et al
    Concurrent Targeting of Glutaminolysis and Metabotropic Glutamate Receptor 1 (GRM1) Reduces Glutamate Bioavailability in GRM1(+) Melanoma.
    Cancer Res. 2019;79:1799-1809.
    PubMed     Abstract available
    
    
    
33. DALLATOMASINA A, Gasparri AM, Colombo B, Sacchi A, et al
    Spatiotemporal Regulation of Tumor Angiogenesis by Circulating Chromogranin A Cleavage and Neuropilin-1 Engagement.
    Cancer Res. 2019;79:1925-1937.
    PubMed     Abstract available
    
    
    
34. DANG N, Lin Y, Rutgeerts O, Sagaert X, et al
    Solid tumor-induced immune regulation alters the GvHD/GvT paradigm after allogenic bone marrow transplantation.
    Cancer Res. 2019 Apr 1. pii: 0008-5472.CAN-18-3143.
    PubMed     Abstract available
    
    
    March 2019
35. SHURIN GV, Kruglov O, Ding F, Lin Y, et al
    Melanoma-induced reprogramming of Schwann cell signaling aids tumor growth.
    Cancer Res. 2019 Mar 26. pii: 0008-5472.CAN-18-3872.
    PubMed     Abstract available
    
    
    
36. REVACH OY, Sandler O, Samuels Y, Geiger B, et al
    Cross-talk between receptor tyrosine kinases AXL and ERBB3 regulates invadopodia formation in melanoma cells.
    Cancer Res. 2019 Mar 26. pii: 0008-5472.CAN-18-2316.
    PubMed     Abstract available
    
    
    
37. KIM E, Zucconi BE, Wu M, Nocco SE, et al
    MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma.
    Cancer Res. 2019 Mar 25. pii: 0008-5472.CAN-18-2331.
    PubMed     Abstract available
    
    
    
38. AMBROSINI G, Do C, Tycko B, Realubit RB, et al
    Inhibition of NF-kappaB-dependent signaling enhances sensitivity and overcomes resistance to BET inhibition in uveal melanoma.
    Cancer Res. 2019 Mar 18. pii: 0008-5472.CAN-18-3177.
    PubMed     Abstract available
    
    
    
39. HENDERSON F, Johnston HR, Badrock AP, Jones EA, et al
    Enhanced fatty acid scavenging and glycerophospholipid metabolism accompanies melanocyte neoplasia progression in zebrafish.
    Cancer Res. 2019 Mar 12. pii: 0008-5472.CAN-18-2409.
    PubMed     Abstract available
    
    
    
40. BENITO-JARDON L, Diaz-Martinez M, Arellano-Sanchez N, Vaquero-Morales P, et al
    Resistance to MAPK inhibitors in melanoma involves activation of the IGF-1R-MEK5-Erk5 pathway.
    Cancer Res. 2019 Mar 4. pii: 0008-5472.CAN-18-2762.
    PubMed     Abstract available
    
    
    February 2019
41. HAYES TK, Luo F, Cohen O, Goodale AB, et al
    A functional landscape of resistance to MEK1/2 and CDK4/6 inhibition in NRAS mutant melanoma.
    Cancer Res. 2019 Feb 28. pii: 0008-5472.CAN-18-2711.
    PubMed     Abstract available
    
    
    
42. TURANI Z, Fatemizadeh E, Blumetti T, Daveluy S, et al
    Optical Radiomic Signatures Derived from Optical Coherence Tomography Images to Improve Identification of Melanoma.
    Cancer Res. 2019 Feb 18. pii: 0008-5472.CAN-18-2791.
    PubMed     Abstract available
    
    
    
43. POZNIAK J, Nsengimana J, Laye JP, O'Shea SJ, et al
    Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma.
    Cancer Res. 2019 Feb 17. pii: 0008-5472.CAN-18-2864.
    PubMed     Abstract available
    
    
    
44. SILBERMAN A, Goldman O, Boukobza Assayag O, Jacob A, et al
    Acid-Induced Downregulation of ASS1 Contributes to the Maintenance of Intracellular pH in Cancer.
    Cancer Res. 2019;79:518-533.
    PubMed     Abstract available
    
    
    January 2019
45. SHIELDS BD, Koss B, Taylor EM, Storey AJ, et al
    Loss of E-cadherin inhibits CD103 anti-tumor activity and reduces checkpoint blockade responsiveness in melanoma.
    Cancer Res. 2019 Jan 23. pii: 0008-5472.CAN-18-1722.
    PubMed     Abstract available
    
    
    
46. FORSBERG EM, Lindberg MF, Jespersen H, Alsen S, et al
    HER2 CAR-T cells eradicate uveal melanoma and T cell therapy-resistant human melanoma in interleukin-2 (IL-2) transgenic NOD/SCID IL-2 receptor knockout mice.
    Cancer Res. 2019 Jan 8. pii: 0008-5472.CAN-18-3158.
    PubMed     Abstract available
    
    
    December 2018
47. BONVIN E, Radaelli E, Bizet M, Luciani F, et al
    Tet2-dependent hydroxymethylome plasticity reduces melanoma initiation and progression.
    Cancer Res. 2018 Dec 11. pii: 0008-5472.CAN-18-1214.
    PubMed     Abstract available
    
    
    
48. WOHLFEIL SA, Hafele V, Dietsch B, Schledzewski K, et al
    Hepatic endothelial Notch activation protects against liver metastasis by regulating endothelial-tumor cell adhesion independent of angiocrine signaling.
    Cancer Res. 2018 Dec 10. pii: 0008-5472.CAN-18-1752.
    PubMed     Abstract available
    
    
    November 2018
49. MASTROIANNI J, Stickel N, Andrlova H, Hanke K, et al
    miR-146a controls immune response in the melanoma microenvironment.
    Cancer Res. 2018 Nov 13. pii: 0008-5472.CAN-18-1397.
    PubMed     Abstract available
    
    
    October 2018
50. RAVINDRAN MENON D, Luo Y, Arcaroli JJ, Liu S, et al
    CDK1 interacts with Sox2 and promotes tumor initiation in human melanoma.
    Cancer Res. 2018 Oct 8. pii: 0008-5472.CAN-18-0330.
    PubMed     Abstract available
    
    
    September 2018
51. DIKSHIT A, Jin YJ, Degan S, Hwang J, et al
    UBE2N promotes melanoma growth via MEK/FRA1/SOX10 signaling.
    Cancer Res. 2018 Sep 17. pii: 0008-5472.CAN-18-1040.
    PubMed     Abstract available
    
    
    
52. PICH C, Meylan P, Mastelic-Gavillet B, Nguyen NT, et al
    Induction of paracrine signaling in metastatic melanoma cells by PPARgamma agonist rosiglitazone activates stromal cells and enhances tumor growth.
    Cancer Res. 2018 Sep 5. pii: 0008-5472.CAN-18-0912.
    PubMed     Abstract available
    
    
    August 2018
53. THRANE K, Eriksson H, Maaskola J, Hansson J, et al
    Spatially resolved transcriptomics enables dissection of genetic heterogeneity in stage III cutaneous malignant melanoma.
    Cancer Res. 2018 Aug 28. pii: 0008-5472.CAN-18-0747.
    PubMed     Abstract available
    
    
    
54. CAPPARELLI C, Purwin TJ, Heilman SA, Chervoneva I, et al
    ErbB3 targeting enhances the effects of MEK inhibitor in wild-type BRAF/NRAS melanoma.
    Cancer Res. 2018 Aug 16. pii: 0008-5472.CAN-18-1001.
    PubMed     Abstract available
    
    
    
55. HUANG M, Qi TF, Li L, Zhang G, et al
    A targeted quantitative proteomic approach assesses the reprogramming of small GTPases during melanoma metastasis.
    Cancer Res. 2018 Aug 2. pii: 0008-5472.CAN-17-3811.
    PubMed     Abstract available
    
    
    July 2018
56. VISHNOI M, Boral D, Liu H, Sprouse ML, et al
    Targeting USP7 identifies a metastasis-competent state within bone marrow-resident melanoma CTCs.
    Cancer Res. 2018 Jul 19. pii: 0008-5472.CAN-18-0644.
    PubMed     Abstract available
    
    
    
57. SHABANEH TB, Molodtsov A, Steinberg SM, Zhang P, et al
    Oncogenic BRAFV600E governs regulatory T cell recruitment during melanoma tumorigenesis.
    Cancer Res. 2018 Jul 19. pii: 0008-5472.CAN-18-0365.
    PubMed     Abstract available
    
    
    June 2018
58. WANG L, Felts SJ, Van Keulen VP, Scheid AD, et al
    Integrative genome-wide analysis of long noncoding RNAs in diverse immune cell types of melanoma patients.
    Cancer Res. 2018 Jun 12. pii: 0008-5472.CAN-18-0529.
    PubMed     Abstract available
    
    
    May 2018
59. HUERGO ZAPICO L, Parodi M, Cantoni C, Lavarello C, et al
    NK cell editing mediates Epithelial to Mesenchymal Transition via phenotypic and proteomic changes in melanoma cell lines.
    Cancer Res. 2018 May 11. pii: 0008-5472.CAN-17-1891.
    PubMed     Abstract available
    
    
    March 2018
60. DAS SK, Pradhan AK, Bhoopathi P, Talukdar S, et al
    The MDA-9/Syntenin/IGF-1R/STAT3 axis directs prostate cancer invasion.
    Cancer Res. 2018 Mar 23. pii: 0008-5472.CAN-17-2992.
    PubMed     Abstract available
    
    
    February 2018
61. YOUNG A, Ngiow SF, Gao Y, Patch AM, et al
    A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment.
    Cancer Res. 2018;78:1003-1016.
    PubMed     Abstract available
    
    
    
62. HOULES T, Gravel SP, Lavoie G, Shin S, et al
    RSK Regulates PFK-2 Activity to Promote Metabolic Rewiring in Melanoma.
    Cancer Res. 2018 Feb 12. pii: 0008-5472.CAN-17-2215.
    PubMed     Abstract available
    
    
    
63. TAYLOR A, Rothstein D, Rudd CE
    Small-Molecule Inhibition of PD-1 Transcription Is an Effective Alternative to Antibody Blockade in Cancer Therapy.
    Cancer Res. 2018;78:706-717.
    PubMed     Abstract available
    
    
    January 2018
64. CAUWELS A, Van Lint S, Paul F, Garcin G, et al
    Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments.
    Cancer Res. 2018;78:463-474.
    PubMed     Abstract available
    
    
    
65. ARNST KE, Wang Y, Hwang DJ, Xue Y, et al
    A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance.
    Cancer Res. 2018;78:265-277.
    PubMed     Abstract available
    
    
    
66. CANALE FP, Ramello MC, Nunez N, Araujo Furlan CL, et al
    CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8(+) T Cells.
    Cancer Res. 2018;78:115-128.
    PubMed     Abstract available
    
    
    December 2017
67. SIMON S, Vignard V, Varey E, Parrot T, et al
    Emergence of High-Avidity Melan-A-Specific Clonotypes as a Reflection of Anti-PD-1 Clinical Efficacy.
    Cancer Res. 2017;77:7083-7093.
    PubMed     Abstract available
    
    
    
68. DIAZ-MARTINEZ M, Benito-Jardon L, Alonso L, Koetz-Ploch L, et al
    miR-204-5p and miR-211-5p contribute to BRAF inhibitor resistance in melanoma.
    Cancer Res. 2017 Dec 11. pii: 0008-5472.CAN-17-1318.
    PubMed     Abstract available
    
    
    
69. YAEGER R, Yao Z, Hyman DM, Hechtman JF, et al
    Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.
    Cancer Res. 2017;77:6513-6523.
    PubMed     Abstract available
    
    
    November 2017
70. WANG G, Mustafi S, Camarena V, Volmar CH, et al
    Vitamin C sensitizes melanoma to BET inhibitors.
    Cancer Res. 2017 Nov 27. pii: 0008-5472.CAN-17-2040.
    PubMed     Abstract available
    
    
    
71. BRIGHTON HE, Angus SP, Bo T, Roques J, et al
    New mechanisms of resistance to MEK inhibitors in melanoma revealed by intravital imaging.
    Cancer Res. 2017 Nov 27. pii: 0008-5472.CAN-17-1653.
    PubMed     Abstract available
    
    
    
72. MO X, Zhang H, Preston S, Martin K, et al
    Interferon-2; signaling in melanocytes and melanoma cells regulates expression of CTLA-4.
    Cancer Res. 2017 Nov 17. pii: canres.1615.2017.
    PubMed     Abstract available
    
    
    
73. HUA KT, Hong JB, Sheen YS, Huang HY, et al
    MicroRNA-519d promotes melanoma progression by downregulating EphA4.
    Cancer Res. 2017 Nov 1. pii: canres.1933.2017.
    PubMed     Abstract available
    
    
    October 2017
74. BLATTNER C, Fleming V, Weber R, Himmelhan BS, et al
    CCR5+ myeloid-derived suppressor cells are enriched and activated in melanoma lesions.
    Cancer Res. 2017 Oct 31. pii: canres.0348.2017.
    PubMed     Abstract available
    
    
    
75. SIERRA RA, Trillo-Tinoco J, Mohamed E, Yu L, et al
    Anti-Jagged Immunotherapy Inhibits MDSCs and Overcomes Tumor-Induced Tolerance.
    Cancer Res. 2017;77:5628-5638.
    PubMed     Abstract available
    
    
    
76. BUCSEK MJ, Qiao G, MacDonald CR, Giridharan T, et al
    beta-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy.
    Cancer Res. 2017;77:5639-5651.
    PubMed     Abstract available
    
    
    
77. COUNTER CM, Crowe MS, Greenberg DN, Brady DC, et al
    Copper Chelation Inhibits BRAFV600E-driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors.
    Cancer Res. 2017 Oct 6. pii: canres.1190.2016.
    PubMed     Abstract available
    
    
    
78. PICCO N, Sahai E, Maini PK, Anderson ARA, et al
    Integrating Models to Quantify Environment-Mediated Drug Resistance.
    Cancer Res. 2017;77:5409-5418.
    PubMed     Abstract available
    
    
    September 2017
79. LI J, Yan S, Liu Z, Zhou Y, et al
    Multiregional sequencing reveals genomic alterations and clonal dynamics in primary malignant melanoma of the esophagus.
    Cancer Res. 2017 Sep 29. pii: canres.0938.2017.
    PubMed     Abstract available
    
    
    
80. WANG JY, Liu GZ, Wilmott JS, La T, et al
    Skp2-mediated stabilization of MTH1 promotes survival of melanoma cells upon oxidative stress.
    Cancer Res. 2017 Sep 25. pii: canres.1965.2017.
    PubMed     Abstract available
    
    
    
81. NEISWENDER JV, Kortum RL, Bourque C, Kasheta M, et al
    KIT suppresses BRAFV600E-mutant melanoma by attenuating oncogenic RAS/MAPK signaling.
    Cancer Res. 2017 Sep 25. pii: canres.0473.2017.
    PubMed     Abstract available
    
    
    
82. LI P, Wuthrick E, Rappaport JA, Kraft C, et al
    GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome.
    Cancer Res. 2017;77:5095-5106.
    PubMed     Abstract available
    
    
    
83. NDOYE A, Budina-Kolomets A, Kugel CH, Webster MR, et al
    ATG5 mediates a positive feedback loop between Wnt signaling and autophagy in melanoma.
    Cancer Res. 2017 Sep 8. pii: canres.0907.2017.
    PubMed     Abstract available
    
    
    
84. DONIA M, Harbst K, van Buuren M, Kvistborg P, et al
    Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNgamma Signaling.
    Cancer Res. 2017;77:4562-4566.
    PubMed     Abstract available
    
    
    August 2017
85. YANG F, Wei J, Zhang S, Zhang X, et al
    Shrimp miR-S8 suppresses the stemness of human melanoma stem-like cells by targeting the transcription factor YB-1.
    Cancer Res. 2017 Aug 30. pii: canres.1375.2017.
    PubMed     Abstract available
    
    
    
86. ZHAO Y, Ting KK, Li J, Cogger VC, et al
    Targeting Vascular Endothelial-Cadherin in Tumor-Associated Blood Vessels Promotes T-cell-Mediated Immunotherapy.
    Cancer Res. 2017;77:4434-4447.
    PubMed     Abstract available
    
    
    
87. ABU EID R, Ahmad S, Lin Y, Webb M, et al
    Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Ex Vivo PI3K-delta Inhibition.
    Cancer Res. 2017;77:4135-4145.
    PubMed     Abstract available
    
    
    July 2017
88. JIANG H, Rivera-Molina Y, Gomez-Manzano C, Clise-Dwyer K, et al
    Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.
    Cancer Res. 2017;77:3894-3907.
    PubMed     Abstract available
    
    
    
89. 
    Retraction: Molecular Mechanism of MART-1+/A*0201+ Human Melanoma Resistance to Specific CTL-Killing Despite Functional Tumor-CTL Interaction.
    Cancer Res. 2017;77:3718.
    PubMed    
    
    
    
90. FERNANDEZ-POMA SM, Salas-Benito D, Lozano T, Casares N, et al
    Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy.
    Cancer Res. 2017;77:3672-3684.
    PubMed     Abstract available
    
    
    June 2017
91. REINHARDT J, Landsberg J, Schmid-Burgk JL, Bibiloni Ramis B, et al
    MAPK signaling and inflammation link melanoma phenotype switching to induction of CD73 during immunotherapy.
    Cancer Res. 2017 Jun 26. pii: canres.0395.2017.
    PubMed     Abstract available
    
    
    
92. YOUNG A, Ngiow SF, Madore J, Reinhardt J, et al
    Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis.
    Cancer Res. 2017 Jun 26. pii: canres.0393.2017.
    PubMed     Abstract available
    
    
    
93. BARTEE MY, Dunlap KM, Bartee E
    Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy.
    Cancer Res. 2017;77:2952-2963.
    PubMed     Abstract available
    
    
    May 2017
94. 
    Correction: Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.
    Cancer Res. 2017;77:2770.
    PubMed    
    
    
    
95. PRAT A, Navarro A, Pare L, Reguart N, et al
    Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma and melanoma.
    Cancer Res. 2017 May 9. pii: canres.3556.2017.
    PubMed     Abstract available
    
    
    
96. LARIMER BM, Wehrenberg-Klee E, Dubois F, Mehta A, et al
    Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response.
    Cancer Res. 2017;77:2318-2327.
    PubMed     Abstract available
    
    
    
97. GUO G, Yu M, Xiao W, Celis E, et al
    Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity.
    Cancer Res. 2017;77:2292-2305.
    PubMed     Abstract available
    
    
    April 2017
98. NIMANONG S, Ostroumov D, Wingerath J, Knocke S, et al
    CD40 Signaling Drives Potent Cellular Immune Responses in Heterologous Cancer Vaccinations.
    Cancer Res. 2017;77:1918-1926.
    PubMed     Abstract available
    
    
    March 2017
99. 
    Correction: Differential Regulation of the Melanoma Proteome by eIF4A1 and eIF4E.
    Cancer Res. 2017;77:1505.
    PubMed    
    
    
    
100. KIRTANE AR, Sadhukha T, Kim H, Khanna V, et al
     Fibrinolytic Enzyme Cotherapy Improves Tumor Perfusion and Therapeutic Efficacy of Anticancer Nanomedicine.
     Cancer Res. 2017;77:1465-1475.
     PubMed     Abstract available
     
     
     
101. MAHNE AE, Mauze S, Joyce-Shaikh B, Xia J, et al
     Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy.
     Cancer Res. 2017;77:1108-1118.
     PubMed     Abstract available
     
     
     February 2017
102. STEINBERG SM, Shabaneh T, Zhang P, Martyanov V, et al
     Myeloid cells that impair immunotherapy are restored in melanomas which acquire resistance to BRAF inhibitors.
     Cancer Res. 2017 Feb 15. pii: canres.1755.2016.
     PubMed     Abstract available
     
     
     January 2017
103. ZHANG T, Xu M, Makowski MM, Lee C, et al
     SDHD promoter mutations ablate GABP transcription factor binding in melanoma.
     Cancer Res. 2017 Jan 20. pii: canres.0919.2016.
     PubMed     Abstract available
     
     
     
104. NEUBERT NJ, Tille L, Barras D, Soneson C, et al
     Broad and conserved immune regulation by genetically heterogeneous melanoma cells.
     Cancer Res. 2017 Jan 19. pii: canres.2680.2016.
     PubMed     Abstract available
     
     
     
105. SEKTIOGLU IM, Carretero R, Bulbuc N, Bald T, et al
     Basophils Promote Tumor Rejection via Chemotaxis and Infiltration of CD8+ T Cells.
     Cancer Res. 2017;77:291-302.
     PubMed     Abstract available
     
     
     November 2016
106. JOYCE CE, Yanez AG, Mori A, Yoda A, et al
     Differential regulation of the melanoma proteome by eIF4A1 and eIF4E.
     Cancer Res. 2016 Nov 22. pii: canres.1298.2016.
     PubMed     Abstract available
     
     
     September 2016
107. XIA T, Konno H, Barber GN
     Recurrent loss of STING Signaling in Melanoma Correlates with Susceptibility to Viral Oncolysis.
     Cancer Res. 2016 Sep 28. pii: canres.1404.2016.
     PubMed     Abstract available
     
     
     
108. KIM M, Neznanov N, Wilfong CD, Fleyshman DI, et al
     Preclinical validation of a single-treatment infusion modality that can eradicate extremity melanomas.
     Cancer Res. 2016 Sep 28. pii: canres.2764.2015.
     PubMed     Abstract available
     
     
     
109. SATOW R, Nakamura T, Kato C, Endo M, et al
     ZIC5 drives melanoma aggressiveness by PDGFD-mediated activation of FAK and STAT3.
     Cancer Res. 2016 Sep 26. pii: canres.0991.2016.
     PubMed     Abstract available
     
     
     
110. CLARK CA, Gupta H, Sareddy GR, Pandeswara S, et al
     Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis and autophagy in ovarian cancer and melanoma.
     Cancer Res. 2016 Sep 26. pii: canres.0258.2016.
     PubMed     Abstract available
     
     
     
111. KLARQUIST J, Tobin K, Farhangi Oskuei P, Henning SW, et al
     CCL22 DIVERTS T REGULATORY CELLS AND CONTROLS THE GROWTH OF MELANOMA.
     Cancer Res. 2016 Sep 12. pii: canres.0618.2016.
     PubMed     Abstract available
     
     
     June 2016
112. HU Y, Lu L, Xia Y, Chen X, et al
     Therapeutic efficacy of cancer stem cell vaccines in the adjuvant setting.
     Cancer Res. 2016 Jun 20. pii: canres.2664.2015.
     PubMed     Abstract available
     
     
     April 2016
113. MENGER L, Sledzinska A, Bergerhoff K, Vargas FA, et al
     TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors.
     Cancer Res. 2016;76:2087-93.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: